The Cytokine response is a major problem in MANY autoimmune diseases . Your list is longer than you think of possible applications and areas for ongoing research. There are any scholarly articles on cytokines and autoimmune diseases . Drugs currently available come with awful side effects . This is an area of further research to require more effective targeting at any stage of the illness requiring a huge heap of money that I just do not see MSB having given the expense and time for trials. It would require a takeover by a major player or some sort of partnering. Anyway its all good for the share price.
- Forums
- ASX - By Stock
- Ann: Remestemcel-L Improves Outcomes in Inflammatory Lung Disease
The Cytokine response is a major problem in MANY autoimmune...
-
- There are more pages in this discussion • 34 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.26 |
Change
-0.050(3.83%) |
Mkt cap ! $1.432B |
Open | High | Low | Value | Volume |
$1.27 | $1.30 | $1.17 | $18.34M | 14.84M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 104582 | $1.25 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.26 | 56681 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
17 | 103526 | 1.250 |
18 | 134769 | 1.245 |
12 | 75865 | 1.240 |
12 | 154981 | 1.235 |
9 | 96273 | 1.230 |
Price($) | Vol. | No. |
---|---|---|
1.255 | 56681 | 17 |
1.260 | 234924 | 14 |
1.265 | 291367 | 18 |
1.270 | 365062 | 16 |
1.275 | 69800 | 4 |
Last trade - 15.07pm 24/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
LGP
LITTLE GREEN PHARMA LTD
Paul Long, CEO
Paul Long
CEO
Previous Video
Next Video
SPONSORED BY The Market Online